Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals.

Nwogu JN, Ma Q, Babalola CP, Adedeji WA, Morse GD, Taiwo B.

AIDS Res Treat. 2016;2016:2587094. Epub 2016 Sep 29. Review.

2.

Prevalence and correlates of probable common mental disorders in a population with high prevalence of HIV in Zimbabwe.

Chibanda D, Cowan F, Gibson L, Weiss HA, Lund C.

BMC Psychiatry. 2016 Feb 29;16:55. doi: 10.1186/s12888-016-0764-2.

3.

An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients.

Swart M, Evans J, Skelton M, Castel S, Wiesner L, Smith PJ, Dandara C.

Front Genet. 2016 Jan 7;6:356. doi: 10.3389/fgene.2015.00356. eCollection 2015.

4.

Incidence and predictors of adverse drug events in an African cohort of HIV-infected adults treated with efavirenz.

Abah IO, Akanbi M, Abah ME, Finangwai AI, Dady CW, Falang KD, Ebonyi AO, Okopi JA, Agbaji OO, Sagay AS, Okonkwo P, Idoko JA, Kanki PJ.

Germs. 2015 Sep 1;5(3):83-91. doi: 10.11599/germs.2015.1075. eCollection 2015 Sep.

5.

Prescription medication misuse among HIV-infected individuals taking antiretroviral therapy.

Newville H, Roley J, Sorensen JL.

J Subst Abuse Treat. 2015 Jan;48(1):56-61. doi: 10.1016/j.jsat.2014.07.013. Epub 2014 Aug 6.

6.

No evident association between efavirenz use and suicidality was identified from a disproportionality analysis using the FAERS database.

Napoli AA, Wood JJ, Coumbis JJ, Soitkar AM, Seekins DW, Tilson HH.

J Int AIDS Soc. 2014 Sep 4;17:19214. doi: 10.7448/IAS.17.1.19214. eCollection 2014.

7.

Long-term safety from the raltegravir clinical development program.

Teppler H, Brown DD, Leavitt RY, Sklar P, Wan H, Xu X, Lievano F, Lehman HP, Mast TC, Nguyen BY.

Curr HIV Res. 2011 Jan;9(1):40-53.

8.

Challenges in addressing depression in HIV research: assessment, cultural context, and methods.

Simoni JM, Safren SA, Manhart LE, Lyda K, Grossman CI, Rao D, Mimiaga MJ, Wong FY, Catz SL, Blank MB, DiClemente R, Wilson IB.

AIDS Behav. 2011 Feb;15(2):376-88. doi: 10.1007/s10461-010-9836-3.

9.
10.

Efavirenz: a decade of clinical experience in the treatment of HIV.

Maggiolo F.

J Antimicrob Chemother. 2009 Nov;64(5):910-28. doi: 10.1093/jac/dkp334. Epub 2009 Sep 18. Review.

Supplemental Content

Support Center